


Now available
Pr_{pms}-PAZOPANIB 200 mg
 Antineoplastic Agent

A generic equivalent
 to VOTRIENT®¹



DIN 02525666
 Pr_{pms}-PAZOPANIB
 200mg



**2D Barcode on blister pack for
 additional product information**



Demonstrated bioequivalent
 to VOTRIENT®¹



Same efficacy and safety
 as the brand^{2,3}



Lower
 cost



Financial assistance
 available

PRODUCT NAME	STRENGTH	FORMAT	DIN	PMS CODE	VISUAL COMPARISON ⁴	
					Pr _{pms} -PAZOPANIB	Pr ¹ VOTRIENT®
Pr _{pms} -PAZOPANIB	200 mg	Blister of 60 tablets	02525666	5760691624		

pms-PAZOPANIB (pazopanib as pazopanib hydrochloride) is indicated for the treatment of patients with metastatic renal cell (clear cell) carcinoma (mRCC) as first-line systemic therapy or as second-line systemic therapy after treatment with cytokines for metastatic disease. pms-PAZOPANIB is also indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.²

pms-PAZOPANIB tablets should be prescribed by a physician experienced in the administration of anti-cancer agents.²





The Ally Patient Support Program

The Ally Program is dedicated to supporting you and your patients. Ally offers financial assistance similar to that of the brand.



FAST FINANCIAL ASSISTANCE⁵

Support for access to treatment when starting on pms-PAZOPANIB for eligible patients.

For more information, please consult: <https://myrx.care/en/ally>

1. VOTRIENT® is a registered trademark owned by NOVARTIS AG.

2. ^Ppms-PAZOPANIB (Pazopanib tablets) Product Monograph. Pharmascience Inc., March 1, 2022.

3. ^PVOTRIENT® (Pazopanib tablets) Product Monograph. Novartis Pharmaceuticals Canada Inc., December 30, 2021.

4. No comparative clinical benefit implied.

5. Restrictions may apply.

In the province of Quebec, Bill 92 amended the Act Respecting Prescription Drug and prohibits manufacturers and wholesalers from reimbursing all or part of the price of a listed drug, provided some exceptions.

YOUR PATIENT SUPPORT PROGRAM 'ALLY' & Design® is a registered trademark owned by Finchley Research & Development Inc., used under licence by Pharmascience Inc.

Together, let's support local businesses!

Choosing Pharmascience® is choosing local, and contributing to the Canadian economy. Pharmascience® employs nearly 1,500 people across the country.

Customer Service: 1-800-340-9735
Medical Information: 1-888-550-6060
www.pharmascience.com

